Rituximab Induction to Prevent the Recurrence of PSC after Liver Transplantation-The Lessons Learned from ABO-Incompatible Living Donor Liver Transplantation-
1Surgery, Keio University School of Medicine, Tokyo, Japan
2Surgery, Institute of Gastroenterology, Tokyo Women's Medical University, Tokyo, Japan
3Division of Hepato-Biliary-Pancreatic Surgery and Transplant Surgery, Kyoto University, Kyoto, Japan
4Hepato-Biliary and Pancreatic Surgery, Okayama University, Okayama, Japan
5Department of Surgery, Kyushu University, Fukuoka, Japan
6Transplantation and Pediatric Surgery, Kumamoto University, Kumamoto, Japan
7Department of Gastroenterological Surgery, Dokkyo Medical University, Tochigi, Japan
8Department of Pediatric Surgery, Fujita Health University School of Medicine, Aichi, Japan.
Meeting: 2018 American Transplant Congress
Abstract number: C209
Keywords: B cells, Liver transplantation, Primary sclerosing cholangitis, Recurrence
Session Information
Session Name: Poster Session C: Liver: Immunosuppression and Rejection
Session Type: Poster Session
Date: Monday, June 4, 2018
Session Time: 6:00pm-7:00pm
Presentation Time: 6:00pm-7:00pm
Location: Hall 4EF
Background: Multiple studies have failed to reveal an effective method for preventing the recurrence of primary sclerosing cholangitis (PSC) after liver transplantation (LTx). A national study conducted in Japan revealed several risk factors for the recurrence after living donor LTx (LDLTx), however, recipients of ABO-blood type incompatible (ABO-I) LTx were excluded from the previous analysis. In the present study, we investigated the efficacy of an immunosuppressive protocol in ABO-I LTx on the recurrence of PSC after LDLTx.
Methods: We conducted a national survey and analyzed the outcome of recipients who underwent ABO-I LDLTx for PSC (n=12) between 1994 and 2010 in 9 centers and compared the outcome with that of ABO-compatible LDLTx for PSC (n=96). The key elements of the immunosuppressive regimen in ABO-I LTx are plasma exchange sessions to remove existing antibodies, and the use of immunosuppression to control humoral immunity. Rituximab was added to the immunosuppression regimen from 2006 onward; 5 patients received rituximab perioperatively.
Results: All 7 recipients who underwent ABO-I LDLTx before 2006 (who did not receive rituximab) died of infection (n=3), antibody mediated rejection (n=1), ABO-incompatibility associated cholangiopathy (n=1) or recurrence of PSC (n=2). In contrast, we found that all 5 recipients from 2006 (who were treated with rituximab) retained an excellent graft function for more than 7 years without any recurrence of PSC.
Conclusions: The findings of this study shed light on the efficacy of a novel strategy to prevent the recurrence of PSC and the possible mechanisms provided by rituximab treatment are discussed.
CITATION INFORMATION: Yamada Y., Hoshino K., Shinoda M., Obara H., Uemoto S., Kaido T., Okajima H., Yagi T., Yoshizumi T., Inomata Y., Hibi T., Kubota K., Suzuki T., Kitagawa Y., Egawa H., Kuroda T. Rituximab Induction to Prevent the Recurrence of PSC after Liver Transplantation-The Lessons Learned from ABO-Incompatible Living Donor Liver Transplantation- Am J Transplant. 2017;17 (suppl 3).
To cite this abstract in AMA style:
Yamada Y, Hoshino K, Shinoda M, Obara H, Uemoto S, Kaido T, Okajima H, Yagi T, Yoshizumi T, Inomata Y, Hibi T, Kubota K, Suzuki T, Kitagawa Y, Egawa H, Kuroda T. Rituximab Induction to Prevent the Recurrence of PSC after Liver Transplantation-The Lessons Learned from ABO-Incompatible Living Donor Liver Transplantation- [abstract]. https://atcmeetingabstracts.com/abstract/rituximab-induction-to-prevent-the-recurrence-of-psc-after-liver-transplantation-the-lessons-learned-from-abo-incompatible-living-donor-liver-transplantation/. Accessed May 11, 2025.« Back to 2018 American Transplant Congress